UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) February 26, 1998

SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)

Delaware	0-26866	95-4343413
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No)

22026 20th Avenue, S.E., Suite 102, Bothell, Washington 98021
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (425) 487-9500

Not Applicable
(Former name or former address, if changed since last report)

Exhibit Index on Page 4

ITEMS 1 THROUGH 4 AND 6 THROUGH 9 NOT APPLICABLE.

ITEM 5 OTHER EVENTS.

Reference is made to the press releases issued to the public by the registrant on February 26, 1998 and March 16, 1998, the text of which are attached hereto as Exhibits 99.1 and 99.2, for a description of the events reported pursuant to this Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SONUS PHARMACEUTICALS, INC.

Date: March 18, 1998 By:

Gregory Sessler
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION	SEQUENTIAL PAGE NO.
99.1	Press Release dated February 26, 1998.	5
99.2	Press Release dated March 16, 1998.	7

EXHIBIT 99.1

NEWS RELEASE

SONUS ANNOUNCES THE FDA HAS REQUESTED ADDITIONAL INFORMATION
REGARDING THE ECHOGEN(R) NDA REVIEW

COMPANY EXPECTS RESPONSE TO LEAD TO APPROVABILITY BY THE FDA

BOTHELL, WASH., February 26, 1998 -- SONUS Pharmaceuticals, Inc. (Nasdaq-NNM: SNUS), today announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that approval of the EchoGen(R) New Drug Application (NDA) requires additional information. The Company expects to be able to provide completely all of the requested information. EchoGen(R) is the Company's proprietary fluorocarbon-based ultrasound contrast agent being investigated to improve ultrasound images for cardiology and radiology.

SONUS received official notice that the FDA has completed its review of the EchoGen(R) NDA and has asked the Company to provide additional information relating to the manufacturing processes, including chemistry and analytical methods validation, and to provide a re-analysis of some of the animal and clinical data. None of the FDA's questions or requests for data are related to the clinical safety of the product as reflected in the clinical trials with EchoGen(R). The Company will be providing these data to the FDA to allow completion of the review by the FDA. Once the issues are addressed to the FDA's satisfaction, SONUS anticipates that the FDA's final determination will be positive.

"Based on substantial additional clinical and pre-clinical work completed since the NDA was filed, we believe we can complete assembly of the information that the FDA has requested within a few weeks, although this period could be extended due to circumstances we cannot directly control," said Steven C. Quay, M.D., Ph.D., president and CEO of SONUS. "Some of the data requires re-analysis, which is underway at this time, and all of our efforts are focused on quickly responding to all remaining issues."

SONUS Pharmaceuticals, Inc., based in Bothell, Wash., is engaged in the research and development of ultrasound contrast agents and drug delivery systems based on its proprietary PhaseShift(TM) and fluorocarbon technology. The Company's products are being investigated to improve the diagnosis and treatment of heart disease, cancer and other debilitating conditions.

-More-

Contact: Investors
Gregory Sessler
SONUS Pharmaceuticals, Inc.
(425) 487-9500

Media
Kelly Ford
SONUS Pharmaceuticals, Inc.
(425) 487-9500

Certain of the statements made in this news release are forward looking such as those relating to the regulatory approval of EchoGen(R). As discussed in SONUS' annual report on Form 10-K filed March 19, 1997, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: EchoGen(R) will require regulatory approval, which approval is subject to certain regulatory requirements and can be lengthy and may include additional requests by the FDA; and market acceptance of EchoGen(R) will depend on a number of factors, including safety, efficacy, ease of administration and the presence of competitive imaging products or technologies. There can be no assurance that the FDA will approve EchoGen(R).

NOTE: SONUS Pharmaceuticals' press releases are available via PR Newswires' Company News on Call service. To receive previous SONUS press releases via fax, dial 1-800-758-5804, ext. 108377. SONUS releases also can be accessed on the Internet at http://prnewswire.com. Additional information about SONUS can be accessed at the SONUS Home Page, http://www.sonuspharma.com.

###

NEWS RELEASE

SONUS ANNOUNCES EMEA COMMITTEE WILL REVIEW ECHOGEN(R)
EMULSION MEDICAL MARKETING APPLICATION

COMPANY ALSO ANNOUNCES MEETING WITH FDA TO DISCUSS RECENT REQUEST FOR
MORE INFORMATION REGARDING ECHOGEN(R) NEW DRUG APPLICATION

BOTHELL, WASH., March 16, 1998 --SONUS Pharmaceuticals, Inc. (Nasdaq-NNM: SNUS), today announced that it has been notified that the Committee for Proprietary Medicinal Products (CPMP) is scheduled to review the EchoGen(R) Emulsion Medical Marketing Application (MMA) at its March meeting later this month. The CPMP is the review arm of the European Medicines Evaluation Agency (EMEA). The committee makes recommendations to the EMEA which typically accepts and ratifies the committee's opinions. EchoGen(R) is the Company's proprietary ultrasound contrast agent being investigated for use in cardiology and radiology applications.

"We are looking forward to this meeting of the CPMP," said Steven C. Quay, M.D., Ph.D, president and CEO of SONUS. "The opinion by the CPMP is the next step toward a Marketing Authorization by the European Commission (EC) which covers the 15 nations of the European Union, including the United Kingdom, Ireland, France, Germany, Italy, Spain, Portugal, Sweden, Finland, Denmark, Belgium, Luxembourg, the Netherlands, Greece and Austria."

The Company also announced that a meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on April 27, 1998. The purpose of this meeting is to discuss the FDA's recent notification requiring additional information regarding the New Drug Application (NDA) for EchoGen(R). While SONUS continues to prepare the information to be submitted in response to the FDA's request, the Company is unable to predict the timing of such a submission until this meeting has taken place.

EchoGen(R) ultrasound contrast agent is a fluorocarbon-based liquid emulsion that turns into a gas microbubble upon syringe activation and injection into the body (a process known as PhaseShift(TM) technology). EchoGen(R) microbubbles travel in the blood stream and enhance the reflected ultrasound signal of the blood resulting in improved ultrasound images.

(-More-)

SONUS Pharmaceuticals, Inc., based in Bothell, Wash., is engaged in the research and development of ultrasound contrast agents and drug delivery systems based on its proprietary PhaseShift(TM) and fluorocarbon technology. The Company's products are being investigated to improve the diagnosis and treatment of heart disease, cancer and other debilitating conditions.

Contact: Investors
Gregory Sessler
SONUS Pharmaceuticals, Inc.
(425) 487-9500

Media
Kelly Ford
SONUS Pharmaceuticals, Inc.
(425) 487-9500

Certain of the statements made in this news release are forward looking such as those relating to the regulatory approval of EchoGen(R). As discussed in SONUS' annual report on Form 10-K filed March 19, 1997, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: EchoGen(R) will require final regulatory approval, which approval is subject to certain regulatory requirements and could be lengthy; and market acceptance of EchoGen(R) will depend on a number of factors, including safety, efficacy, ease of administration and the presence of competitive imaging products or technologies. There can be no assurance that the EC or FDA will approve EchoGen(R).

NOTE: SONUS Pharmaceuticals' press releases are available via PR Newswires' Company News on Call service. To receive previous SONUS press releases via fax, dial 1-800-758-5804, ext. 108377. SONUS releases also can be accessed on the Internet at http://prnewswire.com. Additional information about SONUS can be accessed at the SONUS Home Page, http://www.sonuspharma.com.

###